By: HEIDI SPLETE, Clinical Psychiatry News Digital Network
Major Finding: Depressed patients treated with escitalopram showed significantly decreased activation in the right amygdala when presented with fearful faces, compared to depressed patients treated with a placebo. No changes in mood were observed.
Data Source: A randomized study of 42 depressed adults and 17 healthy volunteers to 10 mg/day of escitalopram or a placebo for 7 days.
Disclosures: The study was funded by the Medical Research Council. Dr. Godlewska had no financial conflicts to disclose.
PARIS – A 7-day treatment of escitalopram significantly decreased the response of the amygdala to fearful stimuli in adults with major depression, Dr. Beata Godlewska reported at the Annual Congress of the European College of Neuropsychopharmacology.
Previous studies in healthy volunteers using functional magnetic resonance imaging (fMRI) have shown that antidepressant treatment reduces emotional responses to negative stimuli.
"Major depression is characterized by negative biases in emotion processing," said Dr. Godlewska, of the department of psychiatry at the University of Oxford (England). "It has been proposed that this change in processing could mediate the therapeutic effect of antidepressants."
Dr. Godlewska and colleagues randomized 42 depressed adults and 17 healthy volunteers to 10 mg/day of escitalopram or a placebo for 7 days. The researchers collected fMRI image information at a magnetic field strength of 3T on the last day of the study, focusing on activity in predetermined regions of interest for the bilateral amygdala. The imaging data consisted of neural responses to presentations happy or fearful faces, but the participants did not know what responses were being measured.
After 7 days, depressed patients treated with escitalopram showed significantly decreased activation in the right amygdala when presented with fearful faces, compared to depressed patients treated with a placebo. "There was no difference in amygdala activation between the escitalopram-treated patients and the healthy controls," Dr. Godlewska said.
Importantly, no clinically significant changes in mood were observed among the different groups during the 7-day study period, Dr. Godlewska noted.
Therefore, the findings suggest that antidepressants improve a depressed patient’s negative affective bias first, and then mood improves, Dr. Godlewska said. This represents a complete change from the currently accepted thinking. "Now people think that improvement in mood is the first stage, and only then the biases change," she said.
This early improvement in negative affective bias could help depressed patients relearn positive emotional associations in a more supportive environment, Dr. Godlewska noted.
More research is needed to determine the clinical implications of the findings, and Dr. Godlewska and colleagues are currently designing a study that would incorporate long-term follow-up data.
The study was funded by the Medical Research Council. Dr. Godlewska had no financial conflicts to disclose.
Interested in being notified of new Depression news?
Click here to view our Depression RSS Feed.
| May 24 - 27 Chicago, IL | Association for Psychological Science (APS): Annual Convention |
| May 29 - Jun 1 Phoenix, AZ | National Institute of Mental Health (NIMH): New Clinical Drug Evaluation Unit (NCDEU) |
| Jun 3 - 7 Stockholm, | Collegium Internationale Neuro-Psychopharmacologicum (CINP): World Congress |
| Jun 5 - 10 Kona, HI | International Behavioral Neuroscience Society (IBNS): Annual Meeting |
| Jun 12 - 17 Chicago, IL | American Psychoanalytic Association (APsaA): 101st Annual Meeting |
| Jun 18 - 26 Rapid City, SD | Reclaiming Youth International: 19th Annual Black Hills Seminars |
| Jun 23 - 27 San Francisco, CA | Research Society on Alcoholism (RSA): Annual Scientific Conference |
| Jul 10 - 13 Liverpool, | Royal College of Psychiatrists: Annual Meeting |
| Jul 21 - 28 Dpart Venice, | Primary Care: Mental Health Issues with a Focus on Drugs and Behavior |
| Jul 21 - 25 Paris, | International Association for Child & Adolescent Psych & Allied Professions (IACAPAP): World Congress |